Dermatology

Changing epidemiology of atopic dermatitis in South Korea

The epidemiology of atopic dermatitis (AD) is heterogeneous across countries and age groups. Traditionally, AD in South Korea has always…

Pipeline Moves: Pfizer’s flu vaccine approval chances rise after Phase III completion

This week on Pipeline Moves, we kick off by looking at a Phase III trial completion of Pfizer’s influenza vaccine…

ARS gears up for neffy US approval

ARS Pharmaceuticals expects to launch neffy (epinephrine nasal spray) in H2 2024, for which the company plans to submit a…

Female vitiligo patients are at an increased risk of osteoporosis

Previously in the literature, an association between those with vitiligo and an increased risk of developing osteoporosis has been speculated.…

Aquestive maps out FDA approval for sublingual anaphylaxis drug

Aquestive Therapeutics has revealed topline data from the Phase III pharmacokinetic (PK) study of its anaphylactic drug, Anaphylm (epinephrine) sublingual…

Sanofi’s amlitelimab shows best-in-class response in atopic dermatitis 

Sanofi has announced encouraging findings from the second part of a study with the OX40 antibody amlitelimab, which showed sustained…

Lilly’s eczema drug shows improvement in people with darker skin tones

Eli Lilly has released results from the Phase III Admirable trial of its monoclonal antibody, lebrikizumab, in patients with darker…

J&J’s JNJ-2113 offers high skin clearance rates in psoriasis trial

Johnson & Johnson (J&J) has reported initial findings from the Phase IIb FRONTIER 2 clinical trial, where JNJ-2113 offered high…

Alphyn gears up for Phase IIb trial for dermatitis treatment

Maryland-based Alphyn Biologics announced that the second cohort in its Phase IIa trial evaluating zabalafin hydrogel (AB-101a) in AD and…

Sanofi looks to advance CSU drug rilzabrutinib in Phase III trial

Sanofi shared positive results from the Phase II trial of rilzabrutinib in patients with moderate to severe chronic spontaneous urticaria…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close